Key result
Empagliflozin added to standard treatment was cost-effective for treating heart failure with reduced ejection fraction in China, yielding an incremental cost-effectiveness ratio of $3,842.20 per QALY.
Why the study?
The pharmacoeconomics of empagliflozin for heart failure with reduced ejection fraction in China needed evaluation to guide clinical rational drug selection and medical decision-making.
Is empagliflozin added to standard therapy cost-effective compared to standard therapy alone for the treatment of HFrEF in China?
Is empagliflozin added to standard therapy cost-effective compared to standard therapy alone for the treatment of HFrEF in China?
Effect estimate: ICER $3,842.20 per QALY
The addition of empagliflozin to standard therapy for HFrEF is highly cost-effective in China, with an ICER well below the willingness-to-pay threshold of one time the per capita GDP.
May support empagliflozin addition for HFrEF in China; leaves open prospective economic confirmation.
Aim: To determine the pharmacoeconomics of empagliflozin for the treatment of heart failure (HF) with reduced ejection fraction in China and to provide evidence-based reference for clinical rational drug selection and medical decision-making. Research design and methods: We used the Markov model to evaluate the cost-effectiveness of empagliflozin for the treatment of HF with reduced ejection fraction (HFrEF). We evaluated the cost-effectiveness of the standard treatment in addition to empagliflozin (empagliflozin group) vs. the cost-effectiveness of the standard treatment alone (standard treatment group). Results: We found that each additional quality-adjusted life year (QALY) in the empagliflozin group costed $3,842.20 more, which was less than China's gross domestic product (GDP) per capita in 2021 ($11,981). The steady-state mortality in the two groups was the key factor affecting the incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis revealed that when the willingness-to-pay (WTP) threshold was one time the GDP per capita in 2021 ($11,981) and three times the GDP per capita in 2021 ($35,943), the probability of the empagliflozin group being cost-effective was 85.8 and 91.6%, respectively. Conclusion: Compared with the standard treatment alone, the addition of empagliflozin to the standard treatment was more cost-effective for the treatment of HFrEF in China.
No takes yet. Share an insight, caveat, or question.
Sang et al. (2022) studied Heart failure with reduced ejection fraction (HFrEF) (n=3,730). Empagliflozin vs. Standard treatment alone was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) (ICER $3,842.20 per QALY). Empagliflozin added to standard treatment was cost-effective for treating heart failure with reduced ejection fraction in China, yielding an incremental cost-effectiveness ratio of $3,842.20 per QALY.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: